MedTrace Logo

Can Measurement of Neutrophil-derived ROS Production be a Novel Biomarker of Sepsis?

NCT05968287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 276

Last updated 2023-08-01

No results posted yet for this study

Summary

Neutrophils are indispensable for host defense and have an important roles in modulating the immune system in both the innate and adaptive immune response. Neutrophils operate using a number of different mechanisms including chemotaxis, phagocytosis, release of reactive oxygen species (ROS) and granular proteins, and the production and liberation of cytokines for this purpose. A controlled neutrophil response is required to combat infection; an dysregulated state of this response can cause sepsis, tissue damage, and organ failure. Sepsis and septic shock are the leading causes of death especially in intensive care units (ICU), and their mortality can be reduced with prompt diagnosis and appropriate treatment modality. From this point of view, many biomarkers have been evaluated for the diagnosis, prognosis, and treatment response of infection and sepsis. An objective marker of cellular dysfunction of neutrophils would be a helpful tool for the clinician in detecting and monitoring changes related to infection status and to determine development of sepsis and positive effects of interventions.

Conditions

Interventions

DIAGNOSTIC_TEST

The Leukocyte ImmunoTest™ (LIT™)

The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.

Sponsors & Collaborators

  • Seroxo Ltd

    collaborator INDUSTRY

  • Gazi University

    lead OTHER

Principal Investigators

  • Nazlıhan Boyacı Dündar, assist.prof. · principle investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-28
Primary Completion
2023-01-27
Completion
2023-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05968287 on ClinicalTrials.gov